NASDAQ: SRRK

Scholar Rock (SRRK) Stock Analysis & Forecast

Nov 13 close

$43.21+0.05 (+0.1%)

Gekko Brief

AI summaryNov 9 close

Scholar Rock advances the commercialization of ISEMBLYD for spinal muscular atrophy, with plans for a 50-country rollout, alongside a reported year-on-year revenue drop and no current profits. Management is also set to speak at the UBS Global Biopharma Conference and the Jefferies Global Healthcare Conference in London on 16 and 17 November. Separately, coverage this week noted shares near $43.98 with a market cap of $5.23 billion as of 3 November, ahead of the move described below.

Shares close at $51.55, up 9.8%, sitting between the 50-day average of $47.01 and the 200-day average of $48.22. The stock's one-month return stands at 22.2%, though the three-month return is -1% and the six-month return is 6.6%; the one-year return is 79%. The GekkoIndex reads 44.4, placing SRRK in the Distribution zone, down from a five-day change of -15. Gekko Fair Value is set at $52.21, putting the current price 1.3% below that level.

Scholar Rock reports earnings on 10 November 2026 before the open, zero days away, falling inside a typical 20-trading-day holding window; the prior print on 6 August 2026 produced a 10.5% reaction, against an average absolute reaction of 8.5% across prior reports. Over the last 90 days, insiders made 4 open-market purchases totaling $11,937,192. Seasonality from this calendar point shows a 22.4% average 20-day return across 5 years, with gains in 3 of them. Analyst coverage includes 15 buy ratings, 1 hold and 0 sell among 16 firms, with a consensus target of $70.44.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Scholar Rock price vs fair value

$51.46$43.21Nov ’25May ’26Nov ’26
Close $43.21200-day averageGekko Fair Value $51.46

Scholar Rock quick facts

Market cap
$5.27B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$3.23
Revenue, TTM
$570K
Profit margin
0%
Dividend yield
—
Beta
0.79
Volume
623,503 avg 1.58M
1-year return
+40.2%
Typical daily move
±6%
Typical 20-day move
±12.3%
50-day average
$46.13
200-day average
$48.24
Next earnings
Mar 2 before open
Shares outstanding
122.0M
52-week range
$29.35$61.76

Scholar Rock swing-trade checklist

Scholar Rock scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive1 mixed1 headwind

  • Trendheadwind

    Below 50 and 200-day

    Close $43.21 is below the 50-day ($46.13) and 200-day ($48.24) averages, and the 50-day is below the 200-day.

    See the chart
  • GekkoIndexmixed

    59.5, Neutral

    Reading 59.5 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    16.0% below

    Price is 16% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: 4 open-market insider purchases.

    See smart money
  • Earnings risksupportive

    Reports in 107 days

    Next report Mar 2, 2027, 107 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +23.7% on average

    From this point in the calendar, the next 20 trading days averaged +23.7% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Scholar Rock stock chart and price history

Scholar Rock closed at $43.21 on Nov 13, 2026, +40.2% over the past year, inside a 52-week range of $29.35 to $61.76.

Close50-day average200-day averageVolume
Scholar Rock share price, past year, with 50-day and 200-day moving averages and volume$30$40$50$60DecJan 2026FebMarAprMayJunJulAugSepOctNov43.21

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+6.3%
3 months
−17.0%
6 months
−12.4%
1 year
+40.2%
The full SRRK chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SRRK in Gekko

Follow Scholar Rock through every session

Put SRRK on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track SRRK in GekkoFree for 7 days. No credit card required.

About Scholar Rock

Scholar Rock is a biopharmaceutical company focused on developing treatments for serious diseases by working with protein growth factor signaling pathways. Its most advanced program is apitegromab, a candidate that blocks the activation of latent myostatin and has completed Phase 3 trials for spinal muscular atrophy. A second program, SRK-181, is in Phase 1 testing for cancers that have grown resistant to standard checkpoint inhibitor drugs such as anti-PD-1 or anti-PD-L1 antibodies.

Beyond these two programs, the company maintains a broader pipeline aimed at neuromuscular disease, cancer, and fibrotic conditions. It has also formed a research collaboration with Gilead Sciences to find and develop inhibitors that target the activation of transforming growth factor beta, with an eye toward treating fibrotic diseases.

Scholar Rock was founded in 2012 and is headquartered in Cambridge, Massachusetts. Its shares trade on the NASDAQ under the ticker SRRK.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
scholarrock.com

Scholar Rock GekkoIndex: the smart money zone

Scholar Rock’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.5, in the Neutral zone, up 8 points over five sessions.

010059.5Neutral

Up 8 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying46+5.7%+8.3%+5.0%+12.3%
Accumulation237+6.0%+6.8%+16.3%+29.9%
Neutral (current zone)389−0.6%+2.0%+4.2%+19.2%
Distribution28+3.2%+5.4%+1.0%+15.4%
Selling2Too few readings yet

Average SRRK share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the SRRK price, zone by zone.Track SRRK in Gekko

Is Scholar Rock stock overvalued? Gekko Fair Value

Scholar Rock trades 16.0% below Gekko Fair Value of $51.46, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Scholar Rock shares are worth, recalculated every trading day.

$51.46

Gekko Fair Value, Nov 14, 2026

16.0% Undervalued

At the end of Aug 2026 the price was 2.2% below the estimate.

Gekko Fair ValueShare price, month end
$51$43Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open SRRK in Gekko

Scholar Rock insider and Congress trading

Insiders filed 4 open-market purchases in Scholar Rock worth $11.94M, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

$11.94Min 4 open-market purchases

FiledInsiderTypeSharesValue
Oct 27AKKARAJU SRINIVAS
director
Purchase97,982$4.08M
Oct 27AKKARAJU SRINIVAS
director
Purchase94,000$3.88M
Oct 27AKKARAJU SRINIVAS
director
Purchase48,988$2.04M
Oct 27AKKARAJU SRINIVAS
director
Purchase47,000$1.94M

From Form 4 filings, dated to when each was filed.

Congress trades last 90 days

No trades in SRRK were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for SRRK, plotted on the chart in Gekko.Open SRRK in Gekko

Hedge funds and billionaires quarter ended Sep 30

0of the funds Gekko tracks hold SRRK.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Scholar Rock earnings: next date and track record

Scholar Rock reports on Mar 2, 2027, before the open (107 days away), and beat the EPS estimate in 2 of its last 8 reports.

2 of 8reports beat the EPS estimate
±8.5%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

−2.7%Nov ’24+4.9%Feb ’25−1.8%May ’25−15.1%Aug ’25+21.3%Nov ’25+9.1%Mar ’26+2.7%May ’26+10.5%Aug ’26

Last earnings call, Aug 6, 2026 AI summary

What they said
Scholar Rock is preparing for the U.S. launch of apitegromab (SMA therapy) with a PDUFA date of September 30, 2026. The BLA was accepted in April after resubmission with two fill/finish facilities, providing dual approval pathways. Commercial teams are launch-ready, vials from both facilities are awaiting packaging upon approval. European MAA is progressing pending FDA inspection classification of Catalent Indiana.
Guidance
Management targets U.S. launch of apitegromab by September 30, 2026 PDUFA date, with teams ready to launch at any time prior. European approval timing guidance will be updated pending regulatory alignment on fill/finish facility inclusion.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 6, 2026−$0.84
est −$0.84
+0.1%—
est $70K
—+10.5%
May 7, 2026−$0.83
est −$0.82
−1.2%—
est $5.00M
—+2.7%
Mar 3, 2026−$0.88
est −$0.88
+0.3%—
est $1.83M
—+9.1%
Nov 14, 2025−$0.90
est −$0.84
−7.8%—
est $50K
—+21.3%
Aug 6, 2025−$0.98
est −$0.66
−48.5%—
est $56K
—−15.1%
May 14, 2025−$0.67
est −$0.63
−6.3%——−1.8%
Feb 27, 2025−$0.60
est −$0.60
0.0%——+4.9%
Nov 12, 2024−$0.66
est −$0.60
−10.7%——−2.7%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Scholar Rock stock forecast and analyst price targets

Analysts’ average 12-month price target for Scholar Rock is $70.44, +63.0% from the last close, from 17 firms rating the stock in the last 90 days.

$70.44consensus 12-month target, +63.0% from the last close
Low $58High $84
Buy15
Hold2
Sell0

Each firm’s latest rating in the last 90 days: 17 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 12Wolfe ResearchHold, downgraded——
Nov 11UBSBuy, maintained$60+38.9%
Nov 11Piper SandlerBuy, maintained$75+73.6%
Nov 11Evercore ISIBuy, maintained$72+66.6%
Nov 11Canaccord GenuityBuy, reiterated$72+66.6%
+4.2%average 20-day move after past Neutral readings
+23.7%average move over the next 20 trading days in the last 5 years
±6%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Scholar Rock seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Scholar Rock averaged +23.7% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−28.9%2021−2.0%2022+76.2%2023+52.7%2024+20.9%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−2.4%3 of 5
Next 10 trading days+5.0%3 of 5
Next 15 trading days+16.1%3 of 5
Next 20 trading days+23.7%3 of 5
Next 30 trading days+25.4%3 of 5

For scale, SRRK’s typical 20-trading-day move in either direction is about 12.3%.

Scholar Rock market cap and key statistics

Scholar Rock’s market cap is $5.27B and revenue of $570K over the last twelve months.

Valuation

Market cap
$5.27B
EPS, TTM
−$3.23
Gekko Fair Value
$51.46

Trading

Volume
623,503
Avg volume, 20 days
1.58M
52-week high
$61.76
52-week low
$29.35
Shares outstanding
122.0M

Financials

Revenue, TTM
$570K
Profit margin
0%
Return on equity
-200%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.79
Typical daily move
±6%
Typical 20-day move
±12.3%

Scholar Rock peers

Scholar Rock’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Scholar Rock stock FAQ

What is Scholar Rock’s market cap?

Scholar Rock’s market cap is $5.27B at the Nov 13, 2026 close of $43.21, with 122.0M shares outstanding.

What is the Scholar Rock stock forecast?

The consensus analyst 12-month price target for Scholar Rock is $70.44, +63.0% from the last close. Of the 17 firms that rated the stock in the last 90 days, 15 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Scholar Rock stock overvalued or undervalued?

On Gekko’s estimate Scholar Rock is undervalued: the Nov 13, 2026 close of $43.21 is 16.0% below Gekko Fair Value of $51.46. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Scholar Rock report earnings next?

Scholar Rock is expected to report on Mar 2, 2027, before the market opens (107 days away). Analysts expect earnings of −$0.42 per share on revenue of $4.33M. Scholar Rock beat the earnings estimate in 2 of its last 8 reports, moving 8.5% on average across the report.

What is Scholar Rock’s 52-week high and low?

Scholar Rock’s 52-week high is $61.76 and its 52-week low is $29.35; it closed at $43.21 on Nov 13, 2026, +40.2% over the past year.

Is Scholar Rock stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (fair value, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Scholar Rock the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.